Karyopharm Theraps patent expiration

1. Xpovio patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9714226 KARYOPHARM THERAPS Hydrazide containing nuclear transport modulators and uses thereof
Jul, 2032

(8 years from now)

US8999996 KARYOPHARM THERAPS Hydrazide containing nuclear transport modulators and uses thereof
Jul, 2033

(8 years from now)

US10519139 KARYOPHARM THERAPS Polymorphs of Selinexor
Aug, 2035

(11 years from now)

US11807629 KARYOPHARM THERAPS Polymorphs of Selinexor
Aug, 2035

(11 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11034660 KARYOPHARM THERAPS Hydrazide containing nuclear transport modulators and uses thereof
Jul, 2032

(8 years from now)

US10544108 KARYOPHARM THERAPS Hydrazide containing nuclear transport modulators and uses thereof
Jul, 2032

(8 years from now)

US9079865 KARYOPHARM THERAPS Hydrazide containing nuclear transport modulators and uses thereof
Jul, 2032

(8 years from now)

US11787771 KARYOPHARM THERAPS Hydrazide containing nuclear transport modulators and uses thereof
Jul, 2032

(8 years from now)

US11753401 KARYOPHARM THERAPS Polymorphs of Selinexor
Aug, 2035

(11 years from now)

US11746102 KARYOPHARM THERAPS Polymorphs of selinexor
Aug, 2035

(11 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-837) Jun 22, 2023
New Chemical Entity Exclusivity(NCE) Jul 03, 2024
ODE*(ODE*) Jun 22, 2027
Orphan Drug Exclusivity(ODE-257) Jul 03, 2026
Orphan Drug Exclusivity(ODE-310) Jun 22, 2027
Orphan Drug Exclusivity(ODE-346) Dec 18, 2027

Drugs and Companies using SELINEXOR ingredient

NCE-1 date: 04 July, 2023

Market Authorisation Date: 03 July, 2019

Treatment: Xpovio is indicated in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy; Xpovio is indicated for the...

Dosage: TABLET

More Information on Dosage

XPOVIO family patents

Family Patents